2013 ACR/ARHP Annual Meeting

October 25-30, 2013. San Diego, CA.

View by Title View Sessions

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 2857

The Role Of FAM173b As a Newly Identified Regulator Of Chronic Pain
Abstract Number: 927

The Role of HIF-1 and HIF-2 During Angiogenesis and Metabolic Adaptation of Human Microvascular Endothelial Cells Towards Hypoxia
Abstract Number: 1724

The Role Of Low-Grade Inflammation In The Association Between Uric Acid and Atherosclerosis: The Codam Study
Abstract Number: 86

The Role Of Meniscal Cells In Osteoarthritis Calcification
Abstract Number: 1162

The Role Of Microrna 155 In Innate Immunity and Arthritis
Abstract Number: 2294

The Role Of Patient Global Disease Activity Score In The Definition Of American College Of Rheumatology/European League Against Rheumatism Remission In Very Early Rheumatoid Arthritis From The Norwegian Very Early Arthritis Clinic
Abstract Number: 1937

The Role Of Rural Residence In Low Back Pain
Abstract Number: 957

The Role Of S100A4 As a Biological Marker Of Immune Response In Early Rheumatoid Arthritis
Abstract Number: 218

The Role Of Salivary GLAND Ultrasound In Sjogren Syndrome: A Single Center Experience
Abstract Number: 907

The Role Of Social Relationships and Perceived Independence In The Employment Participation Of Young Adults With Rheumatic Disease
Abstract Number: 1280

The Role of Sphingosine-1-Phosphate Receptor 3 Signaling in Murine Collagen-Induced Arthiritis
Abstract Number: 2573

The Role Of STAT-3 In The Development Of Pulmonary and Dermal Fibrosis
Abstract Number: 2908

The Roles Of Nurse Practitioners and Physician Assistants In Rheumatology Practices In The United States
Abstract Number: 1650

The Route Of T Cell Priming Determines The Requirement For IL-23 In The Development Of Arthritis
Abstract Number: 771

The S100A9 Inhibitor Paquinimod (ABR-215757) Reduces Synovial Activation, Osteophyte Formation and Cartilage Damage In Experimental Osteoarthritis

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].